TY  - JOUR
TI  - A Meta-analysis for Prevalence of Lung Cancer Patients with
SARS-CoV-2 Infection during the COVID-19 Pandemic
AB  - Objectives: Cancer patients were found to be at higher risk of infection with severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) and experienced more adverse outcomes. The objective of this meta-analysis was to estimate
the prevalence of lung cancer patients with SARS-CoV-2 infection during the COVID-19 pandemic.
Methods: A comprehensive search was carried out on PubMed, Web of Science, Scopus, MedRxiv, SciELO, SID, CNKI,
and Wanfang databases to retrieve all relevant publications. All cross-sectional studies and consecutive case series on
cancer patients with SARS-CoV-2 infection were selected.
A total of 28 studies including 5400 infected cancer patients and 767 lung cancer patients with COVID-19 were included.
Results: Combined data indicated that the prevalence of lung cancer patients with SARS-CoV-2 infection was 15.2% (95%
CI, 0.111–0.205) overall. Stratified analysis by ethnicity showed that the prevalence was 16.4% and 15.4% in Asian and
Caucasian lung cancer patients with COVID-19, respectively. Moreover, subgroup analysis by country of origin showed
that the prevalence was highest in China (19.3.0%) followed by France (12.6%), the UK (10.7%), and the USA (8.3%).
Conclusion: This meta-analysis revealed that the prevalence of lung cancer patients with SARS-CoV-2 infection during
the COVID-19 pandemic was 15.2%.
AU  - Asadian, Fatemeh
AU  - NATAJ, Mohsen Gholi
AU  - Neamatzadeh, Hossein
AU  - MİRJALİLİ, Hamid
AU  - VAKİLİ, Mohammad
AU  - DASTGİRİ, Ahmad Shirinzadeh
AU  - RAFIEIAN, Shahab
AU  - ERSHADİ, Reza
AU  - BARAHMAN, Maedeh
DO  - 10.14744/ejmo.2022.50535
PY  - 2022
JO  - Eurasian Journal of Medicine and Oncology
VL  - 6
IS  - 1
SN  - 2587-2400
SP  - 73
EP  - 82
DB  - TRDizin
UR  - http://search/yayin/detay/521047
ER  -